Your browser is no longer supported. Please, upgrade your browser.
Settings
PPH VanEck Vectors Pharmaceutical ETF daily Stock Chart
PPH [NASD]
VanEck Vectors Pharmaceutical ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week0.91%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-4.63%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter1.81%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio20.71 Perf Half Y-2.63%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year5.36%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range50.35 - 60.47 Perf YTD5.92%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-8.02% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low10.46% ATR0.58
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)45.51 Volatility0.84% 1.02%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.19 Prev Close56.00
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume46.63K Price55.62
Recom- SMA20-0.04% SMA50-2.40% SMA200-1.38% Volume55,353 Change-0.68%
Nov-14-17 02:35PM  Understanding Sanofis Revenues by Segment in 3Q17 Market Realist
Oct-16-17 12:33PM  President Trump reiterates that drug companies 'getting away with murder' but says not much else MarketWatch
Oct-02-17 12:35PM  CORRECTING and REPLACING Announcing VanEck Vectors Equity ETFs September 2017 Distributions Business Wire
Sep-29-17 05:25PM  Announcing VanEck Vectors Equity ETFs September 2017 Distributions Business Wire
Sep-20-17 10:36AM  Why Cosentyx Could Significantly Drive Novartiss Revenue Growth Market Realist
Sep-19-17 10:38AM  An Update on Novartiss Sandostatin, Afinitor, and Exjade Market Realist
Sep-14-17 07:39AM  TEVA Depends on This for Revenue Growth Market Realist
Sep-11-17 10:36AM  How Mercks Gardasil and Other Human Vaccines Performed in 2Q17 Market Realist
07:36AM  Where Jazz Pharmaceuticals Erwinaze and Prialt Are Positioned after 2Q17 Market Realist
Sep-06-17 09:06AM  Performance of AstraZenecas Other Products in 2Q17 Market Realist
Sep-05-17 07:37AM  Performance of AstraZenecas Growth Platforms in 2Q17 Market Realist
Sep-04-17 09:06AM  Performance of Eli Lillys Neuroscience Products in 2Q17 Market Realist
Aug-31-17 12:34PM  Changes in GlaxoSmithKlines Valuation after 2Q17 Market Realist
07:38AM  How Novartiss Sandoz Performed in 2Q17 Market Realist
Aug-30-17 07:36AM  Johnson & Johnsons Medical Devices Segment in 2Q17 Market Realist
Aug-23-17 11:53AM  JAZZ Is Focused on Increasing Market Adoption of Defitelio Market Realist
09:53AM  Jazz Pharmaceuticals Is Focused on Label Expansion of Defitelio Market Realist
Aug-21-17 04:05PM  Inside Jazzs Net Profit Margin Expectations for 2017 Market Realist
Aug-17-17 07:37AM  Sanofis Revenue Growth in 2Q17 Market Realist
Aug-15-17 09:06AM  Pfizers Important Product Developments in 2Q17 Market Realist
Aug-14-17 10:25AM  Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isnt Worth the Risk InvestorPlace
Aug-07-17 09:53AM  How Valeant Pharmaceuticals Intl Inc (VRX) Stock Can Make a Comeback InvestorPlace
Aug-01-17 11:21AM  Buy Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Before Q2 Earnings InvestorPlace
07:41AM  GlaxoSmithKlines 2Q17 Earnings: Business Segments Market Realist
Jul-31-17 06:05PM  Bristol-Myers Squibbs 2Q17 Earnings: Opdivo Market Realist
Jul-28-17 05:05PM  Eli Lilly in 2Q17: Performance of New Products Market Realist
Jul-27-17 07:44AM  Analysts Recommendations for AstraZeneca in 2Q17 Market Realist
Jul-25-17 04:25PM  Inside GlaxoSmithKlines 2Q17 Earnings Estimates Market Realist
Jul-24-17 01:05PM  Foreign Exchange Impacts Novartiss Growth in 2Q17 Market Realist
10:37AM  Johnson & Johnson: Consumer Products in 2Q17 Market Realist
Jul-17-17 10:39AM  Analysts Latest Recommendations for Johnson & Johnson Market Realist
10:27AM  Novartiss 2Q17 Earnings: Analyst Estimates Market Realist
Jul-11-17 09:07AM  Farxiga Could See Robust Demand in International Markets in 2017 Market Realist
Jul-10-17 03:10PM  What Lies Ahead for Pharma ETFs in Second Half 2017 Zacks
07:39AM  What We Can Expect from Eli Lilly and Company in 2Q17 Market Realist
Jul-04-17 10:37AM  Johnson & Johnsons Pharmaceuticals Business in 1Q17 Market Realist
07:36AM  Keytrudas Developments in June 2017 Market Realist
Jul-03-17 09:10AM  AstraZeneca May Witness a Fall in 2017 Net Profit Margin Market Realist
Jun-30-17 05:27PM  Announcing VanEck Vectors Equity ETFs June 2017 Distributions Business Wire
Jun-28-17 10:36AM  Pfizers Profitability in 1Q17 Market Realist
Jun-21-17 09:08AM  Analyzing Bristol-Myers Squibbs Valuation on June 20 Market Realist
Jun-20-17 12:09PM  SK Biotek to Acquire Manufacturing Facility in Swords, Ireland Market Realist
Jun-08-17 09:06AM  What Drove Pfizer in 1Q17? Market Realist
Jun-02-17 07:36AM  Inside Novartiss Generics Business Now Market Realist
Jun-01-17 10:37AM  GlaxoSmithKlines Consumer Healthcare Segment in 1Q17 Market Realist
May-24-17 09:06AM  Gardasil and Mercks Vaccines Business in 1Q17 Market Realist
May-18-17 09:07AM  Behind Bristol-Myers Squibbs 1Q17 Performance Market Realist
May-09-17 09:06AM  Comparing Pfizers Valuation to Peers after 1Q17 Earnings Market Realist
May-02-17 10:36AM  How GlaxoSmithKlines Consumer Healthcare Segment Fared in 1Q17 Market Realist
07:38AM  Analyzing GlaxoSmithKlines Global Pharmaceutical Performance Market Realist
May-01-17 07:39AM  Eli Lillys 1Q17 Earnings: Humalog and Other Endocrine Products Market Realist
Apr-28-17 09:08AM  1Q17 Earnings for Novartiss Alcon, Its Eye Care Business Market Realist
Apr-27-17 09:08AM  Dupixent Expected to Be a Solid Addition to Regenerons Portfolio Market Realist
Apr-26-17 12:05PM  What Analysts Recommend for AstraZeneca Market Realist
10:37AM  A Look at Bristol-Myers Squibbs Other Segments in 1Q17 Market Realist
Apr-24-17 09:07AM  Novartiss 1Q17 Estimates for Alcon Market Realist
Apr-21-17 03:05PM  Analysts Expect Novartiss Revenues to Remain Flat in 1Q17 Market Realist
10:36AM  Eli Lillys Estimate for Strattera, Other Neuroscience Products Market Realist
Apr-17-17 12:17PM  5 ETFs to Buy If You Love Johnson & Johnson's First-Quarter Earnings TheStreet.com
Apr-14-17 07:37AM  Analyzing Johnson & Johnsons Medical Devices Segment Market Realist
Apr-04-17 09:06AM  Is Sanofi Pasteur Living Up to Its Name? Market Realist
09:06AM  Is Sanofi Pasteur Living Up to Its Name?
Apr-03-17 10:39AM  What Have Clinical Trials of Novartiss LEE011 Demonstrated? Market Realist
10:39AM  What Have Clinical Trials of Novartiss LEE011 Demonstrated?
09:07AM  The Latest from Sanofis Diabetes and Cardiovascular Franchise Market Realist
09:07AM  The Latest from Sanofis Diabetes and Cardiovascular Franchise
07:36AM  Novartis Is Focused on Creating Shareholder Value in 2017 Market Realist
07:36AM  Novartis Is Focused on Creating Shareholder Value in 2017
Mar-31-17 06:16PM  Announcing VanEck Vectors Equity ETF's March 2017 Distributions Business Wire
09:06AM  How Eli Lillys Neuroscience Franchises 2016 Turned Out Market Realist
09:06AM  How Eli Lillys Neuroscience Franchises 2016 Turned Out
Mar-30-17 09:06AM  GlaxoSmithKlines Consumer Healthcare Segment in 2016 Market Realist
09:06AM  GlaxoSmithKlines Consumer Healthcare Segment in 2016
Mar-29-17 10:36AM  Cosentyx Enjoys Solid Demand as Psoriasis Therapy in Europe Market Realist
10:36AM  Cosentyx Enjoys Solid Demand as Psoriasis Therapy in Europe
09:06AM  Performance of Key Pharmaceuticals Products for GlaxoSmithKline Market Realist
09:06AM  Performance of Key Pharmaceuticals Products for GlaxoSmithKline
Mar-28-17 10:39AM  GlaxoSmithKlines Segment-Wise Performance in 2016
07:36AM  How 2016 Treated Alcon, Novartiss Eyecare Business
Mar-24-17 09:05AM  Valeants Diversified Products Revenue May Drop in 2017
Mar-22-17 09:07AM  How AstraZeneca Controlled Operating Expenses in 2016
07:37AM  Headwinds Seen by Valeant Pharmaceuticals in 2016
Mar-21-17 07:37AM  Analysts Recommendations for Valeant Pharmaceuticals in 2017
Mar-17-17 10:37AM  What Cardiovascular Drug Eliquiss 2016 Looked Like
Mar-15-17 04:33PM  Should You Buy Pharma ETFs Now?
07:36AM  Johnson & Johnsons Major Developments
Mar-10-17 02:17PM  Trump administration expected to name VC partner Gottlieb to head FDA at MarketWatch
Mar-08-17 11:06AM  The Bears Take Aim at Pharmaceuticals (PPH, PJP) at Investopedia
07:07AM  Demand offers big opportunity in health care stocks: Pro
Mar-07-17 09:58AM  Healthcare ETFs in Focus on Obamacare Replacement Plan
Mar-06-17 07:36AM  How Did Mylans Rest of the World Segment Perform?
Mar-01-17 09:06AM  Emerging Markets Expected to Be AstraZenecas Key Growth Driver
08:23AM  Bernie Sanders has some new allies in fight to bring Canadian drugs to the U.S. at MarketWatch
Feb-28-17 07:36AM  Pfizers Profitability and Financial Guidance
Feb-27-17 02:35PM  AstraZenecas 4Q16 Revenues Fell 12%
07:36AM  Eli Lilly & Co.s Neuroscience Franchise
Feb-24-17 07:39AM  Performance of Eli Lilly & Co.s Business Segments in 4Q16
Feb-23-17 01:50PM  What Analysts Recommend for Teva Pharmaceutical in 2017
10:37AM  Remicade: Driving Down Merck & Co.s Immunology Franchise
Feb-22-17 09:08AM  Merck & Co.s Segment-Wise Revenues for 4Q16
VanEck Vectors ETF Trust - VanEck Vectors Pharmaceutical ETF is an exchange traded fund launched and managed by Van Eck Associates Corporation. The fund invests in public equity markets of the United States. It invests in the stocks of companies operating in the pharmaceutical sector, including companies involved in pharmaceutical research and development as well as production, marketing, and sales of pharmaceuticals. The fund invests in the stocks of companies across all market capitalizations, with market capitalization greater than $150 million. It seeks to replicate the performance of the MVIS US Listed Pharmaceutical 25 Index, by investing in the stocks of companies as per their weightings in the index. The fund was formerly known as Market Vectors ETF Trust - Market Vectors Pharmaceutical ETF. VanEck Vectors ETF Trust - VanEck Vectors Pharmaceutical ETF was formed on February 1, 2000 and is domiciled in the United States.